Lundbeck is to cut yet more jobs in Europe as the Danish pharma firm restructures its operations to focus on …
Takeda and Lundbeck’s treatment for major depressive disorder has demonstrated a significant improvement in patients’ symptoms during trials. Brintellix (Vortioxetine) …
Lundbeck’s sales and profit increase in the first three months of 2013 was due largely to one-off payments it received, …

The loss of US patent protection on antidepressant Lexapro has put a significant dent in Lundbeck’s financial performance for 2012. …
Neurological disorder specialist Lundbeck has posted a modest growth in revenue for the third quarter, but warned the looming patent …
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals

